...and a baseline IOP of >=23 mmHg showed that once-daily 0.375%, 0.75%, 1.125% and 1.5% bamosiran...
...twice-daily 0.5% timolol in reducing IOP from baseline to day 28. The 1.125% dose of bamosiran...
...subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A. , Madrid, Spain Product: Bamosiran ( SYL040012...

...after "all of the trial's variables have been analyzed." Sylentis S.A. , Madrid, Spain Product: SYL040012...

...Sylentis said it began a placebo-controlled, dose-ranging, European Phase II trial to evaluate daily SYL040012 eye...
...is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A. , Madrid, Spain Product: SYL040012...

...Zeltia's Sylentis S.A. subsidiary began an open-label, Spanish Phase I/II trial to evaluate SYL040012 ophthalmic drops...
...administered once daily for 7 days in 30 patients. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...

...SYL040012 ophthalmic drops given once daily in 30 patients. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...

...single-blind, Spanish Phase Ia trial showing that subjects displayed "excellent" local and systemic tolerance to SYL040012...
...to start Phase I/II testing as soon as possible. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...

...In a rabbit model of hypertension, SYL040012 prevented intraocular pressure increase and ocular hypertension induced by...
...Research in Vision and Ophthalmology meeting in Fort Lauderdale. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...